Retatrutide + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Overweight or Obesity
Conditions
Overweight or Obesity, CKD, Type 2 Diabetes
Trial Timeline
Jul 20, 2023 → Oct 21, 2025
NCT ID
NCT05936151About Retatrutide + Placebo
Retatrutide + Placebo is a phase 2 stage product being developed by Eli Lilly for Overweight or Obesity. The current trial status is completed. This product is registered under clinical trial identifier NCT05936151. Target conditions include Overweight or Obesity, CKD, Type 2 Diabetes.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (12)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07232719 | Phase 3 | Recruiting |
| NCT06982846 | Phase 1 | Active |
| NCT07035093 | Phase 3 | Recruiting |
| NCT06859268 | Phase 3 | Active |
| NCT06383390 | Phase 3 | Active |
| NCT06354660 | Phase 3 | Completed |
| NCT06297603 | Phase 3 | Active |
| NCT05931367 | Phase 3 | Completed |
| NCT05936151 | Phase 2 | Completed |
| NCT05929079 | Phase 3 | Active |
| NCT05929066 | Phase 3 | Active |
| NCT05882045 | Phase 3 | Active |
Competing Products
20 competing products in Overweight or Obesity